[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medtronic - MITG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,84,108,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100530577","randomized-trial-of-ui-ewd-vs-conventional-endoscopic-therapy-for-nonvariceal-upper-gastrointestinal-bleeding-100530577",false,"NCT06188585","Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding","Randomized Controlled Multi-Center Non-Inferiority Trial of UI-EWD (Nexpowder™) vs. Conventional Treatment as First-Line Endoscopic Therapy for Patients With High-Risk Nonvariceal Upper Gastrointestinal Bleeding (TREET)","TREET","Inclusion Criteria:\n\n1. Adults age 22 years or older\n2. Presentation with acute overt gastrointestinal bleeding (hematemesis, melena, and\u002For hematochezia)\n3. Subject voluntarily agrees to participate in the clinical investigation, provides written informed consent, and will be able to comply with the investigational protocol in the opinion of the site investigator\n4. Cause of bleeding as determined at upper endoscopy is one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear. The definition of \"active oozing\" will require bleeding to persist for ≥ 3 minutes of endoscopic observation.\n\nExclusion Criteria:\n\n1. Incarceration\n2. Subjects that are not able to provide written informed consent\n3. Pregnancy or nursing mothers\n4. Endoscopic hemostatic treatment in the past 30 days\n5. Use of triple antithrombotic therapy at the time of presentation\n6. Subjects who underwent gastric or duodenal endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) procedures within the past 2 months\n7. Post-polypectomy bleeding\n8. Subjects with erosive esophagitis, erosive gastritis, esophageal ulcer, or vascular ectasia including gastric antral vascular ectasia\n9. Platelet count \\\u003C 50 x 10\\^9\u002FL\n10. INR \\> 3.5 (or prothrombin time \\>35 seconds in patient not on warfarin and only prothrombin time is provided by local lab), at time of procedure or closest to procedure time\n11. Subjects who have documented galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\n12. Subjects with documented hypersensitivity to Brilliant Blue FCF\n13. Subjects with suspected bowel obstruction or gastrointestinal fistulas, and those suspected or are at high risk of having gastrointestinal perforation.\n14. Endoscopy not performed within 36 hours of presentation to hospital\u002Femergency department","ALL","22 Years",{"count":20,"type":21},278,"ESTIMATED","INTERVENTIONAL",[24],"NA","A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.",[27],"Acute Gastrointestinal Bleeding",[29,30,31],"Gastrointestinal hemorrhage","Peptic Ulcer","Nonvariceal upper gastrointestinal bleeding","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2024-06-21",{"date":40,"type":21},"2029-09",{"name":42,"class":43},"Medtronic - MITG","INDUSTRY",14,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":70,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100619934","post-market-study-of-the-signia-circular-stapler-with-tri-staple-technology-in-left-sided-colon-sigmoid-and-rectal-resections-100619934","NCT07351071","Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections","A Prospective, Multicenter, Single-arm, Post Market Study to Evaluate the Safety and Performance of the Signia™ Circular Stapler With Tri-Staple™ Technology in Elective Open or Minimally Invasive Left-sided Colon, Sigmoid, and Rectal Resections (SECURE)","SECURE","Preoperative Inclusion Criteria:\n\n1. Subject is competent and willing to provide documented informed consent to participate in this clinical study\n2. Subject is intended to undergo an elective left sided colon\u002Fcolorectal procedure where a creation of an anastomosis will be completed with the Signia™ circular stapler\n3. Subject is ≥ 18 years of age at time of consent\n\nPreoperative Exclusion Criteria:\n\n1. Subject is unable or unwilling to comply with the study requirements or follow-up schedule\n2. Subject with ASA classification ≥ IV\n3. Subject is pregnant (as determined by standard site practices)\n4. The procedure is an emergency procedure\n5. The procedure is a revision\u002Freoperation for the same indication\n6. The subject has a documented confounding medical condition which in the opinion of the investigator, will not be appropriate for the study, or the subject has an estimated life expectancy of less than 6 months\n7. Subject has participated or plans to participate in an investigational drug or device research study that would interfere with the results of this study\n8. Subject will undergo multiple synchronous colon resections\n9. Subject with a bleeding disorder or is undergoing anticoagulant treatment that has not been reversed (anticoagulant prophylaxis prescribed as part of the surgical protocol is allowed)\n10. Subject has undergone chemotherapy or received biologics within 6 weeks prior to the day of the procedure\n11. Subject has history of chronic corticosteroid use (used greater than 3 months within a year prior to the index procedure)\n12. Subject has chronic immunosuppression therapy (used greater than 3 months within a year prior to the index procedure)\n13. Any subject undergoing an ileal-anal pouch anastomosis surgery\n\nIntraoperative Exclusion Criteria\n\n1. Anastomosis not attempted with the Signia™ circular stapler\n2. Any subject for which the device is intended to be used outside the instructions for use (IFU)","18 Years",{"count":55,"type":21},137,[24],"The purpose of this study is to evaluate the safety and performance of the Signia™ power handle, Signia™ circular adapter, and Signia™ Tri-Staple™ 2.0 circular reloads (hereafter referred to as Signia™ circular stapler) in patients undergoing left sided colon, sigmoid, or rectal resections in a post market setting.",[59,60,61,62,63,64,65,66,67,68,69],"Colorectal Anastomosis","Left-sided Colon Resection","Anastomotic Leak","Anastomotic Complication","Digestive System Diseases","Gastrointestinal Diseases","Colonic Diseases","Intestinal Diseases","Rectal Diseases","Postoperative Complications","Anastomotic Leaks",[59,60,71,61,72,73,74],"Circular stapler","Rectal cancer","Low anterior resection","Powered stapler","2026-06-11",{"date":77,"type":36},"2026-06-12",{"date":79,"type":36},"2025-12-30",{"date":81,"type":21},"2027-02-28",{"name":42,"class":43},9,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":53,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100610953","nellcor-investigational-device-sitting-walking-study-100610953","NCT07234279","Nellcor™ Investigational Device Sitting-Walking Study","Feasibility of the Investigational Nellcor™ Investigational Device During Non-Motion and Walking Motion Conditions in Adult Volunteers","Inclusion Criteria:\n\n* Male or female participants ≥18 years of age, and \\\u003C75 years of age.\n* Participant is able to participate for the duration of the study\n* Participant is willing to sign an informed consent form (ICF)\n* Participant weighs \\> 40kg\n* Participants must be a non-smoker or not have smoked within 36 hours prior to the study\n\nExclusion Criteria:\n\n* Participant self-reported prior injury or trauma to fingers or hands, which in the opinion of the investigator, may change blood flow or vascular supply and affect the ability to test sensors\n* Physiologic abnormalities that prevent proper application of pulse oximetry sensor\n* Severe contact allergies that cause a reaction to standard adhesive materials such as those found in medical sensors and electrodes\n* Individuals of childbearing potential who are self-reported as pregnant, or who are self-reported as trying to get pregnant\n* Morbid obesity (defined as BMI \\> 39.5)\n* Weight \\> 136 kg\n* Participants who self-report problems of unsteadiness or imbalance issues and\u002For who are unable to walk on a treadmill without holding onto the handrails\n* Participant self-reported known heart or cardiovascular conditions such as:\n* Uncontrolled hypertension (Systolic pressure ≥ 140mmHg or Diastolic pressure \\> 90mmHg on 3 consecutive readings day of screening)\n* Heart arrhythmias other than sinus arrhythmia (Self-reported and\u002For as identified on ECG day of screening).\n* History of heart attack, blocked artery, history of myocardial ischemia, angina, myocardial infarction, congestive heart failure, cardiomyopathy, stroke, transient ischemic attack, or carotid artery disease\n* Participants with self-reported clotting disorders, such as:\n* History of bleeding disorders or personal history of prolonged bleeding from injury\n* History of blood clots\n* Hemophilia\n* Current use of prescription blood thinner\n* Participants with other self-reported, known health conditions, such as:\n* Diabetes\n* Thyroid disease\n* Kidney disease \u002F chronic renal impairment\n* History of seizures (except childhood febrile seizures), epilepsy, or unexplained syncope\n* Recent history of frequent migraine headaches, as determined medically relevant by the PI\n* History of head injury, as determined medically relevant by the PI\n* Cancer \u002F chemotherapy\n* Sickle cell disease\n* History of hospital admission or a surgical procedure in the 60 days prior to study enrollment (self-reported)\n* Participants with any contraindications to protocol specific repositioning techniques\n* Unwillingness or inability to remove colored nail polish from test digit(s)\n* Participants who have self-reported health conditions beyond what is captured in the prior exclusion criteria, which in the opinion of the Investigator and\u002For Clinical Staff would classify the participant as medically unsuitable",true,"75 Years",{"count":94,"type":21},30,"OBSERVATIONAL","To examine pulse rate and blood oxygen saturation accuracy of the Nellcor™ Investigational Device during non-motion and walking motion conditions in a diverse patient population through non-invasive means",[98],"Oxygen Saturation","NOT_YET_RECRUITING","2026-05-12",{"date":102,"type":36},"2026-05-14",{"date":104,"type":21},"2026-06",{"date":106,"type":21},"2026-07",{"name":42,"class":43},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":91,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100565121","continuous-connected-patient-care-ccpc-a-pilot-testing-a-novel-device-for-continuous-vitals-monitoring---older-adults-department-phc-100565121","NCT06638060","Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Older Adults Department PHC","Inclusion Criteria:\n\n* Inpatients on the Acute care of the Elderly ward.\n\nExclusion Criteria:\n\n* Lack of capacity to consent to the study including moderate-severe dementia or delirium\n* Unable to use (or does not have a caregiver who can help put on) study monitoring device at home\n* Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone\n* Patient with known allergic reactions to any part material of the device\n* People under 40kg","65 Years",{"count":116,"type":21},15,"To confirm feasibility and accessibility of the CCPC Platform (Oxymotion, Bridge Health Solutions medication adherence software, CloudDX home kit) in two different environments - 1) hospital (Acute Care for Elderly Unit) and 2) at-home .",[119],"Aging","2026-03-10",{"date":122,"type":36},"2026-03-12",{"date":124,"type":36},"2025-03-13",{"date":126,"type":21},"2026-06-21",{"name":42,"class":43},1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":128},"100565122","continuous-connected-patient-care-ccpc-a-pilot-testing-a-novel-device-for-continuous-vitals-monitoring---department-of-anesthesia-at-phc-100565122","NCT06638073","Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Department of Anesthesia at PHC","Inclusion Criteria:\n\n* 19 years or older\n* Patients that have undergone a non-cardiac surgery at SPH requiring an inpatient hospital stay\n* Peri-op patients who are in the Surgical High Acuity Unit (SHAU) and those followed by Anesthesia Perioperative Outreach team on the ward\n* Living within British Columbia, Canada and in an area that is covered by Bell cellular network\n\nExclusion Criteria:\n\n* Patient refusal\n* Lack of capacity to consent to the study (including having received sedative or general anesthetic within the past 24 hours)\n* Unable to use (or does not have a caregiver who can help put on) study monitoring device at home\n* Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone\n* No access to cell phone nor landline at home to receive follow-ups\n* Preoperatively known to be discharged to a nursing home or rehabilitation facility\n* Known allergic reactions to any part material of study devices","19 Years",{"count":137,"type":21},50,"To confirm feasibility and accessibility of the CCPC Platform (Oxymotion, Bridge Health Solutions medication adherence software, CloudDX home kit) in two different environments - in hospital and at-home, in patients undergoing non-cardiac surgery.",[140,141],"Surgical Procedure, Unspecified","Intensive Care Units (ICUs)",{"date":122,"type":36},{"date":124,"type":36},{"date":145,"type":21},"2026-06-20",{"name":42,"class":43},""]